An IND application represents months of preclinical work distilled into regulatory documentation. Yet a single missing data point or unjustified claim can trigger a clinical hold, delaying first-in-human studies by months. The FDA Submission Readiness Companion reviews draft documents against FDA and ICH expectations before submission, identifying gaps that could derail your timeline.
The IND Documentation Challenge
FDA requires three core elements for IND approval: animal pharmacology and toxicology studies demonstrating reasonable safety, manufacturing information on composition and stability, and clinical protocols with investigator qualifications [1]. Each element must meet specific standards - CMC sections need thorough characterization of identity, purity, potency, and stability; toxicology modules require GLP-compliant studies per 21 CFR Part 58.
The challenge is ensuring consistency across documents while meeting evolving ICH guidelines (S6, S7A, S7B, S8) for preclinical studies. Manual review is time-consuming and error-prone.
How the Companion Works
The FDA Submission Readiness Companion ingests draft IND-supporting documents and systematically checks them against regulatory expectations:
Input: Three Draft IND-Supporting Documents
Investigator_Brochure.pdf
CMC_Module3.pdf
Toxicology_Module4.pdfThese documents undergo automated review for completeness, internal consistency, and alignment with current FDA guidance.
Gap Detection in Action
Consider a real example - a draft stability report for Compound XZ-401:
Output: Draft Stability Report with Identified Gap
| Time Point | Capsule Appearance | Assay | Impurities |
|---|---|---|---|
| 0 months | Unchanged | 100.6% | <0.1 |
| 6 months | Unchanged | 99.8% | <0.5 |
| 12 months | <82-test | <82.0% | <0.5 |
GAP IDENTIFIED: Only 12-month data available. Retest period not justified.
This gap - insufficient stability data to support the proposed retest period - would likely trigger FDA questions. ICH Q1A requires stability data supporting the proposed shelf life; 12 months of data alone cannot justify extended dating without statistical extrapolation or additional evidence [2].
Common Gaps the Companion Catches
CMC Module: Missing batch analysis data, incomplete impurity profiles, inadequate container closure justification, stability protocols not aligned with ICH Q1A/Q1B.
Toxicology Module: GLP compliance statements missing, exposure margins not calculated, recovery group data incomplete, species selection not justified.
Investigator Brochure: Inconsistent data between modules, missing risk mitigation strategies, outdated reference safety information.
From Weeks to Hours
Traditional regulatory review involves consultants spending weeks cross-referencing documents against guidance. The Companion compresses this to hours, generating prioritized gap reports that regulatory teams can act on immediately.
The 30-day FDA review clock starts upon submission [3]. Every gap caught before filing is a potential clinical hold avoided.
Regulatory submissions succeed on completeness and consistency. The FDA Submission Readiness Companion ensures both before the FDA review begins.
References
[1] FDA. "Investigational New Drug (IND) Application." https://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-application
[2] FDA. "IND Applications for Clinical Investigations: Chemistry, Manufacturing, and Control (CMC) Information." https://www.fda.gov/drugs/investigational-new-drug-ind-application/ind-applications-clinical-investigations-chemistry-manufacturing-and-control-cmc-information
[3] PMC. "Understanding FDA Regulatory Requirements for Investigational New Drug Applications for Sponsor-Investigators." https://pmc.ncbi.nlm.nih.gov/articles/PMC4435682/